New hope for mesothelioma: drug targets cancer from two angles
NCT ID NCT06840834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called ivonescimab in 38 people with pleural mesothelioma whose cancer has returned after immunotherapy and chemotherapy. The drug works by blocking blood vessel growth and boosting the immune system to fight cancer. The main goal is to see if the drug can stop the cancer from growing for at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (a drug that targets blood vessel growth and the immune system)
What this could lead to
If successful, this could offer a new treatment option for patients with pleural mesothelioma whose cancer has returned after standard therapies.
What could go wrong
This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Besançon - CHU
RECRUITINGBesançon, France
-
Bordeaux - CHU
RECRUITINGPessac, France
-
Brest - CHU
RECRUITINGBrest, France
-
Caen - CHU
RECRUITINGCaen, France
-
Clermont-Ferrand - Centre Jean Perrin
RECRUITINGClermont-Ferrand, France
-
Créteil - CHI
RECRUITINGCréteil, France
-
Grenoble - CHU
RECRUITINGGrenoble, France
-
Le Mans - CHG
RECRUITINGLe Mans, France
-
Lille - CHU
RECRUITINGLille, France
-
Lyon - HCL
RECRUITINGPierre-Bénite, France
-
Marseille - APHM
RECRUITINGMarseille, France
-
Metz - Hôpital Robert Schuman
RECRUITINGVantoux, France
-
Montpellier - CHU
RECRUITINGMontpellier, France
-
Mulhouse - GHRMSA
RECRUITINGMulhouse, France
-
Nantes - Hôpital Laennec
RECRUITINGNantes, France
-
Paris - Bichat
RECRUITINGParis, France
-
Strasbourg - Nouvel Hôpital Civil
RECRUITINGStrasbourg, France
-
Toulon - CHI
RECRUITINGToulon, France
-
Toulouse - CHU
RECRUITINGToulouse, France
-
Tours - CHU
RECRUITINGTours, France